| 纯度 | >90% SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK4 |
| Uniprot No | P11802 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-303aa |
| 氨基酸序列 | ATSRYEPVAEIGVGAYGTVYKARDPHSGHFVALKSVRVPNGGGGGGGLPISTVREVALLRRLEAFEHPNVVRLMDVCATSRTDREIKVTLVFEHVDQDLRTYLDKAPPPGLPAETIKDLMRQFLRGLDFLHANCIVHRDLKPENILVTSGGTVKLADFGLARIYSYQMALTPVVVTLWYRAPEVLLQSTYATPVDMWSVGCIFAEMFRRKPLFCGNSEADQLGKIFDLIGLPPEDDWPRDVSLPRGAFPPRGPRPVQSVVPEMEESGAQLLLEMLTFNPHKRISAFRALQHSYLHKDEGNPE |
| 预测分子量 | 37.6kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK4重组蛋白的3篇参考文献示例(文献信息为模拟概括，供参考)：
---
1. **文献名称**：*Structural Insights into CDK4 Regulation by Recombinant Protein Expression and Inhibitor Binding*
**作者**：Miller, A. et al.
**摘要**：通过重组表达技术在大肠杆菌中制备活性CDK4蛋白，解析其晶体结构，揭示了小分子抑制剂与CDK4激酶结构域的特异性结合模式，为靶向药物设计提供依据。
2. **文献名称**：*Optimization of Recombinant CDK4 Production in Insect Cells for Functional Kinase Assays*
**作者**：Chen, L. & Wang, Y.
**摘要**：研究利用杆状病毒-昆虫细胞系统高效表达CDK4重组蛋白，优化纯化条件并验证其激酶活性，成功应用于高通量抑制剂筛选及体外磷酸化功能分析。
3. **文献名称**：*CDK4-Cyclin D1 Complex Formation Studied via Co-expression of Recombinant Proteins in Mammalian Systems*
**作者**：Roberts, S. et al.
**摘要**：通过共表达重组CDK4和Cyclin D1蛋白，阐明二者复合物的组装机制及对细胞周期G1/S转换的调控作用，为癌症治疗中靶向复合物的策略提供实验基础。
---
**注**：以上文献信息为示例性概括，实际引用需以真实发表的论文为准。建议通过PubMed或Web of Science搜索关键词“CDK4 recombinant protein”“CDK4 expression/purification”等获取具体文献。
**Background of CDK4 Recombinant Protein**
Cyclin-dependent kinase 4 (CDK4) is a serine/threonine kinase that plays a crucial role in regulating the cell cycle transition from the G1 phase to the S phase. It functions by forming a complex with D-type cyclins (cyclin D1. D2. or D3), which phosphorylates and inactivates the retinoblastoma (Rb) protein. This phosphorylation releases transcription factors like E2F, enabling the expression of genes required for DNA replication and cell cycle progression. Dysregulation of CDK4 activity, due to gene amplification, mutations, or overexpression of cyclin D, is frequently implicated in various cancers, making CDK4 a prominent therapeutic target.
Recombinant CDK4 protein is engineered using biotechnology platforms, such as bacterial (e.g., *E. coli*) or mammalian expression systems, to ensure high purity and activity. The recombinant form retains the kinase function of native CDK4. allowing researchers to study its biochemical properties, interaction with cyclins, and inhibitory responses to small-molecule inhibitors (e.g., palbociclib, ribociclib) in controlled settings.
Its applications span drug discovery, mechanistic studies of cell cycle regulation, and screening for anticancer agents targeting the CDK4/cyclin D/Rb pathway. Recombinant CDK4 also aids in understanding resistance mechanisms to CDK4/6 inhibitors, which are widely used in treating hormone receptor-positive breast cancers. By providing a standardized and scalable protein source, recombinant CDK4 accelerates both basic research and therapeutic development in oncology and cell biology.
×
